AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06064474 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo HVBR
Description: Placebo
Study NCT05490589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EQUIPE Program
Description: EQUIPE is a manualised group community-based parent education programme. Groups consist of 15 parents who meet with one or two trained group leaders for weekly 2-hour sessions over 10 weeks.~This program promotes skill development in parents, strengthens relationships with children, increases cooperation, and helps solve problems in the home.
Study NCT05019950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily oral tablet
Study NCT05295147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palmar Grasp Reflex Stimulation
Description: The palmar grasp reflex is an involuntary flexion-adduction movement involving the hands and fingers.
Study NCT06512896 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FOLactis
Description: Evaluate the safety,tolerability, efficacy of intraluminal injection of FOLactis combined with chemotherapy, target therapy, and immunotherapy
Study NCT05709470 — intervention group
Intervention type: OTHER
Intervention: No-intervention
Description: Observational cross-sectional study design with no intervention
Study NCT04914091 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interviews and self-administered questionnaires
Description: Interviews and questionnaires will be performed before administration of CAR-T cells, 3 month after and 6 month after, and will last 60 minutes each time. Semi-structured interview using pre-established questionnaires will be completed with a hospital pharmacist, concerning the patient's perception of his family, socio-professional environment, his knowledge of his illness and his treatment, the consumption of prescribed drugs outside the hospital, self-medication, complementary alternative therapies including herbal medicine. Seven self-administered questionnaires will be completed, concerning quality of life, Assessment of Cancer Treatment-Lymphoma, Beliefs about Medicines, Brief Illness Perception, satisfaction with medication, perceived social support scale, and on Health Literacy.
Study NCT05102747 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated SRT (stereotactic radiotherapy)
Description: 3\*10Gy over 1 week
Study NCT05102747 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Historical single-dose SRS (stereotactic radiosurgery)
Description: 20 to 25Gy/1 fraction
Study NCT05329259 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: One dose of 13vPnC (0.5mL) will be administered intramuscularly.
Study NCT06099106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEPIOLA System
Description: Implantation of the SEPIOLA device into the left atrial appendage.
Study NCT04893018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efineptakin alfa
Description: Given IM
Study NCT06227689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccine chatbot that offering HPV vaccine-related information
Description: The intervention group will be invited to use the HPV vaccine chatbot online through WeChat or any web browsers, where they can ask any questions related to the HPV vaccine and get previously validated answers from the chatbot immediately. All the answers will be drawn from a database, whose content were obtained from official websites of Chinese government, HPV vaccine enterprises, and International organizations like WHO, and had been validated by experts. The intervention lasts two weeks, with invitations sent every four days to reinforce the intervention.
Study NCT06335589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EBP-Massed
Description: CPT or PE will be delivered in a massed format (e.g., sessions at least 3 days per week)
Study NCT06335589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EBP-TAU
Description: CPT or PE will be delivered treatment as usual, which is typically once per week.
Study NCT05883566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimental
Description: During the procedure, the chairside assistant can capture video recordings of the child's behavior and facial expressions. These videos can be later reviewed by a trained observer who can evaluate the child's pain experience
Study NCT05564364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Recumbent Bike
Description: The first group will exercise with a recumbent bike for 20 minutes, 3 sessions/week for 6 weeks.
Study NCT05564364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upright Bike
Description: The first group will exercise with a upright bike for 20 minutes, 3 sessions/week for 6 weeks.
Study NCT05237713 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Canakinumab Injection
Description: Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years
Study NCT05528601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: use of Endo App®
Description: use of Endo App® smartphone application containing endometriosis relevant exercises and educational material
Study NCT02985671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orphenadrine, acetaminophen, caffeine and diclofenac sodium
Description: orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg tablet
Study NCT05020964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab and Pyrotinib
Description: Trastuzumab: 3-week dosing regimen, The initial load dose was 8 mg/kg. Pyrotinib: 400 mg orally once daily, take it continuously, every 21 days as a cycle.~Use until intolerable toxicity or disease progression occurs.
Study NCT02677636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSRD-100
Description: MSRD-100 is a topical gel.
Study NCT02677636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle is a topical gel without the active ingredients in MSRD-100
Study NCT05257148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofenopril 30 mg
Description: Film-Coated tablets administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
Study NCT05257148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol 5 mg
Description: Tablet administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
Study NCT05257148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofenopril 30 mg + Nebivolol 5 mg
Description: Both Film coated tablets of Zofenopril 30 mg and Nebivolol 5 mg Tablets will be taken in the morning (from 6 am to 10 am) with no restriction on food intake
Study NCT02985671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium 50 MG
Description: Voltaren (diclofenac sodium 50mg) tablet
Study NCT02985671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for experimental drug)
Description: tablet without active substances, manufactured to mimic experimental product tablet
Study NCT02985671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Voltaren)
Description: tablet without active substances, manufactured to mimic Voltaren 50mg tablet
Study NCT05578183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: theta burst stimulation
Description: expect for the TBS, all patients get cognitive training alike on a training system in medical center.
Study NCT05578183 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: expect for the TBS, all patients get cognitive training alike on a training system in medical center.
Study NCT05650840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Charcoal based whitening toothpaste (signal charcoal white& Detox toothpaste Unilever Mashreq - Egypt
Description: The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded.~Intervention drug : whitening toothpaste charcoal based whitening toothpaste compared to calcium carbonate and perlite whitening toothpaste~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush (Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination
Study NCT05650840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate /perlite containing whitening toothpaste (signal whitening moonlight toothpaste Unilever Mashreq - Egypt).
Description: The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using calcium carbonate /perlite containing toothpaste. Soft bristles toothbrushes will provided to all patients (Oral-B). After 1 month, re-evaluation of the stains will be performed and the data will be recorded. The main operator will perform the tooth brushing procedures for all the patients himself twice daily.~FOR IN VITRO:~Human premolars will be obtained from volunteers due to orthodontic reasons. Teeth will be divided into two equal groups (n:18) according to the toothpaste used. Teeth will be brushed with an electric tooth brush(Oral-B PRO 500) that will be held in a holder to standardize the position to the tooth surface for 3 minutes equivalent to 2 times a day for one month. Teeth will be prepared for AFM examination Device used is atomic force microscopy to determine enamel abrasion after brushing
Study NCT04594473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Oncology Rehabilitation and Exercise (CORE) Program
Description: \[see arm/group descriptions\]
Study NCT05864508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: intranasal oxytocin treatment once a day during 6 weeks
Study NCT05333666 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: This investigation aims to collect and analyze the data from a cohort. During the cohort development, all participants received venous puncturing for NOAC concentration measurement. However, the standard treatment protocol was not changed after study enrollment. In this retrospective cohort study, we only collect data from the cohort without further intervention to the participants.
Study NCT04666181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: See descriptions under arm description. The dual-task training will occur across a total of 5 consecutive workday visits.
Study NCT05178511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Ensaritinib was taken orally once 225mg, on an empty stomach or with food, until the patient developed disease progression, developed unacceptable toxicity, the investigator or subject decided to drop out, lost follow-up, initiated other antitumor therapy, or died
Study NCT06085040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary weight loss
Description: 12-months multidisciplinary behavioral intervention combining physical activity (3 times 60 minutes per week), nutritional guidance (balanced meals) and psychological support (60 minutes per week)
Study NCT04961125 — intervention group
Intervention type: GENETIC
Intervention: germline variants
Description: Variants of 139 genes associated with different hereditary cancers and polyposis were screened by next-generation sequencing.
Study NCT05248776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL207280
Description: IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).
Study NCT05248776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet.
Study NCT06492421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times.
Study NCT05040867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Description: The physical exercise programme will last 16 weeks where participants will do three weekly sessions of 60 minutes, approximately. In these training sessions, cardiovascular and strength components will be worked out, planned from moderate to high intensity in the TEG and unique high intensity in the HRVG. The training programme will be divided into three mesocycles from neuromuscular adaptation to reach, in last period, the highest loads and cardiovascular levels. Each session will include a warm-up, a main part and a cool-down with stretching and mobility exercises.~The difference between the interventions of the HRVG and TEG will be in the planning of the intensity of the cardiovascular exercises and the weight to be lifted in the strength exercises. The first session of both programmes will have the same intensity but depending on how the heart rate variability of the HRVG patients reacts to, the weight and the intensity will be individualised each day.
Study NCT04247191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-Chat
Description: The P-Chat is a brief individually delivered intervention based on the principles of Motivational Interviewing (MI) and focuses on increasing parents' motivation to reduce permissiveness toward underage alcohol use while reducing defensiveness and barriers to implementing these rules with their teen.
Study NCT04247191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PBI
Description: The PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of the two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third, is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young.
Study NCT04247191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-Chat+
Description: The P-Chat+ is a combination of the P-Chat and PBI described above. Parents in this arm of the study will receive both interventions.
Study NCT05123404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multi parametric MRI
Description: In our study we aim to evaluate role of Multiparametric MRI in differentiation between invasive and non-invasive bladder cancer and accuracy of vesical imaging reporting and data system (VI-RADS) score.
Study NCT05123404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transurethral resection of bladder tumor
Description: detection of degree of invasion to test accuracy of ViRADS score
Study NCT06499142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parakeet:The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample.
Description: The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample. The Parakeet is a point of care test completely controlled by the surgeon and operating team. It uses the scientific principle of Lateral Flow of antibody-antigen-conjugate complexes being arrested in a Test Line.
Study NCT05537974 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endotracheal aspiration
Description: Clearance of endotracheal secretions via a catheter.
Study NCT06370481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Routine care administered via telemedicine
Study NCT06370481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care, as received in HIV clinic settings
Study NCT06205329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01 Dose 1-4
Description: WPV01 Dose 1-4 or Placebo on day 1
Study NCT06205329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01 Dose 5-8 and Ritonavir
Description: WPV01 Dose 5-8 and Ritonavir or Placebo on day 1
Study NCT06205329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01 Dose 9-12
Description: WPV01 Dose 9-12 or Placebo from day 1 to day 6
Study NCT06205329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01 Dose 13-15 and Ritonavir
Description: WPV01 Dose 13-15 and Ritonavir or Placebo from day 1 to day 6
Study NCT06205329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01 Dose 16
Description: Cohort 1:WPV01 Dose 16 or Placebo (with high fat meal) Cohort 2:WPV01 Dose 16 or Placebo (fasted)
Study NCT04969549 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Theta burst stimulation
Description: It consists of 20 sessions of iTBS over the dlPFC.
Study NCT05991882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 1: Craving daily+PBS daily
Description: Participants in this condition will complete ecological momentary assessment (EMA) for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and protective behavioral strategy (PBS) messages, each delivered once daily, until the end of the six-week period.
Study NCT05991882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 2: Craving daily+PBS trigger
Description: Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
Study NCT05991882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 3: Craving trigger+PBS daily
Description: Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages that will be delivered based on responses to signal-contingent EMA questions and PBS delivered once daily.
Study NCT05991882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 4: Craving trigger+PBS trigger
Description: Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered based on responses to signal-contingent EMA questions.
Study NCT05991882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condition 5: PBS daily+ PBS trigger
Description: Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive PBS messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
Study NCT05341999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold saline (cryotherapy)
Description: using 20ml of 2.5°C cold saline for 5 min
Study NCT05341999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: patients will be prescribed ibuprofen medication as a single dose immediately after completion of root canal treatment.
Study NCT05341999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Final irrigation with normal saline
Description: final irrigation will be done using normal saline at room temperature.
Study NCT05187754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based breathing therapy program
Description: Participant caregivers of palliative patients were randomized into the intervention and the control groups. Prior to randomization, participants and nurses were informed online abut the aim of the research and their written consent was obtained. Once the study ended, mindfulness-based breathing therapy were recommended to the patients in the control group. Data were collected online via Google forms survey and the interviews were conducted online via Zoom.